INTRODUCTION
The seven-transmembrane-helix receptors (7TMRs) comprise a large and diverse family of cell-surface receptors that on agonist binding can bind and activate a G protein and subsequently initiate diverse signaling events. Some ligands also stimulate G protein-independent pathways (Pierce et al., 2002) ; unless otherwise stated, the terms ''agonist '' and ''antagonist,'' etc. refer to the G protein-coupled pathway (see Box 1 for pharmacological definitions). The 7TMRs are the largest single class of drug target (Wise et al., 2002) , and the b-adrenoceptors (bARs) are the targets of beta blockers (antagonists of the G proteincoupled pathway) in the treatment of heart failure, as well as agonists used in asthma therapies. Recent structures of both the b 1 -adrenoceptor (b 1 AR) and the b 2 -adrenoceptor (b 2 AR) have led to an understanding of the molecular characteristics that define an agonist compared to an inverse agonist and how an agonist promotes the activation of a G protein (Cherezov et al., 2007; Hanson et al., 2008; Moukhametzianov et al., 2011; Wacker et al., 2010; Warne et al., 2008 Warne et al., , 2011 . The structures of the inactive states (R) of bARs when bound to antagonists are very similar, although there are some differences in the region of the ''ionic lock'' depending on whether the salt bridge between Arg 3.50 and Glu 6.30 is present or not (superscripts refer to the Ballesteros Weinstein nomenclature (Ballesteros and Weinstein, 1995) ). When full agonists bind to the R state, the most significant effects are the contraction of the binding pocket and the change in rotamer conformation of Ser 5.46 , implying that these are a prerequisite to the attainment of the activated state (R*) that can couple to G proteins . In contrast to agonists, partial agonists apparently do not form a hydrogen bond to Ser 5.46 , which explains their decreased efficacy . The structure of b 2 AR bound to either a G protein mimetic or Gs shows that the agonists bind to R* in the same manner as to the R state and that the intracellular regions of helices 5 and 6 move by 10-14 Å upon activation (Rasmussen et al., 2011a; Rasmussen et al., 2011b) . The challenge over the coming years is to relate the structures of the bARs bound to various ligands and the pharmacological effects of drugs targeting bARs in humans, particularly where the ligands also stimulate G protein-independent pathways, such as through interactions with arrestin.
In the classical view of 7TMR-ligand interactions, agonists bind to receptors and stimulate the activity of specific G proteins to varying degrees, whereas inverse agonists block the effects of agonist activation and also inhibit constitutive signaling. In this view, sometimes termed linear efficacy, the signaling processes associated with a drug's activity are in proportion to its efficacy and therefore its position on the scale of effects ranging from that of a full to an inverse agonist of a G protein, as was shown in early studies on the b 2 AR (Benovic et al., 1988) . It is now clear that this is an oversimplification, and the more recent concept of biased agonist function has evolved in response to a body of evidence that shows that 7TMRs can interact directly with other signaling partners, for example, arrestin. These alternative G protein-independent signaling pathways can be selectively stimulated alongside G protein activation, and a ligand's efficacy can be ''biased'' more or less to different pathways (Rajagopal et al., 2010; Violin and Lefkowitz, 2007) . In addition to the implied requirement for distinct conformational states to explain these receptor activities (Kenakin, 2001) , there is also a growing realization that existing drugs that target 7TMRs may have more complex effects than first realized, and that the concept of ligand bias may therefore allow the development of more effective therapies (Whalen et al., 2011 ).
Carvedilol and bucindolol are both beta blockers (antagonists) that target b 1 AR (see Figure 1 for the structures of ligands) and can also bind to b 2 AR. However, both bucindolol and carvedilol have also been shown to stimulate non-G protein-coupled pathways of bARs (i.e., they are biased agonists). With the human b 1 AR, bucindolol has been found to act as a partial agonist of the G protein-signaling pathway as well as an agonist of the mitogen-activated protein kinase (MAPK) pathway through a G protein-independent mechanism (Galandrin et al., 2008) . This suggests that bucindolol can induce a signaling conformation of b 1 AR that is distinct from both conventional (G protein) antagonist-bound and agonist-bound states (Galandrin et al., 2008) . All conventional bAR agonists can enhance arrestin-mediated signaling as a functional consequence of their activation of the G protein-signaling pathway (Drake et al., 2008; Wisler et al., 2007) . However, carvedilol is an inverse agonist of G protein signaling, but it stimulates arrestin-mediated signaling pathways of both human b 2 AR and mouse b 1 AR independently of G protein-mediated signaling (Kim et al., 2008; Wisler et al., 2007) . Because of these unique properties, its interactions with bARs will be of interest as it has been suggested that carvedilol could be a prototype for the design of a new generation of therapeutic agents that could stimulate arrestin-dependent signaling, with potentially increased cardioprotective effects, to a greater extent than current beta blockers (Nobles et al., 2011; Noma et al., 2007; Wisler et al., 2007) .
The major structural changes that result in binding and activation of a G protein by a 7TMR include large outward movements of transmembrane helices 5 and 6 (Rasmussen et al., 2011b) , but the receptor conformational changes that might promote arrestin-mediated signaling or signaling through other G protein-independent pathways in preference to G protein activation are at present unknown. In the case of the b 2 AR, ligands that stimulate arrestin signaling are thought to cause conformational changes at the receptor's C terminus, and these might promote phosphorylation and facilitate interactions with regulatory proteins such as arrestin (Granier et al., 2007) . Small increases in phosphorylation levels of the b 2 AR C terminus have been demonstrated for some arrestin-biased agonists, including carvedilol (Drake et al., 2008) , and the resulting pattern of phosphorylation is distinct from that promoted in response to stimulation with the nonbiased agonist, isoprenaline (Nobles et al., 2011) .
Bucindolol and carvedilol are clearly of interest in relation to their role in the activation of non-G protein-mediated signaling pathways, and, in addition, they are also being studied with respect to two isoforms of human b 1 AR in the treatment of congestive heart failure. A common single nucleotide polymorphism occurs in amphipathic helix 8 (H8) of human b 1 AR, where Arg389 8.56 is substituted by Gly in 20%-40% of the population depending on ethnicity (Maqbool et al., 1999) . The Arg/Gly389 polymorphism results in a significant variation in G protein activation, with b 1 AR-Arg389 having a slightly higher basal activity and a 3-fold increased adenylyl cyclase activity on stimulation with the nonbiased agonist isoprenaline compared to b 1 ARGly389 (Mason et al., 1999) . Both carvedilol and bucindolol have been shown to be more effective than other beta blockers as inverse agonists of b 1 AR-Arg389 (Liggett et al., 2006; Rochais et al., 2007) , findings which were initially heralded as a starting point for personalized therapies in heart failure (DeGeorge and Koch, 2007; Pleger and Koch, 2006) . In order to elucidate the interactions of these ligands with the receptor as a foundation for further studies of signaling with biased agonists, and to determine possible reasons for the enhanced activities of the ligands on b 1 AR-Arg389, we have determined the cocrystal structures of a thermostabilized avian b 1 AR with bucindolol and carvedilol.
RESULTS AND DISCUSSION
Structures of b 1 AR Bound to Bucindolol and Carvedilol The avian b 1 AR was modified to allow crystallization by the removal of flexible regions at the N terminus, C terminus, and in cytoplasmic loop 3, and the introduction of 8 point mutations (see Experimental Procedures), to give the construct b 1 AR44-m23. Six of the point mutations result in thermostabilization of b 1 AR , which allows crystallization in short-chain detergents (Warne et al., 2008) . A consequence of thermostabilization is that the receptor is preferentially in the antagonist-bound state (R) (Serrano-Vega et al., 2008), although b 1 AR-m23 is capable of binding agonists with a similar rank Agonist. A ligand that binds to and activates a receptor and elicits a physiological response. The endogenous agonist for the b 1 AR is noradrenaline, which is a full agonist that elicits the maximal response for the receptor in activating a G protein.
Constitutive or basal activity. Physiological response that occurs in the absence of any receptor-activating ligand due to a fraction of the receptor being in an activating conformation. Inverse agonist. A ligand that binds to a receptor and inhibits or eliminates, in the case of a full inverse agonist, the basal or constitutive activity of a receptor. Partial agonist or partial inverse agonist. Ligands that elicit only a partial response when compared to either a full agonist or a full inverse agonist, respectively. Antagonist. Any ligand that blocks binding of endogenous agonists to the receptor, thereby modulating receptor activity. A general term that encompasses ligands that may be inverse agonists, partial agonists, or neutral in effect. Beta blockers. Term for antagonists of bARs when used in a therapeutic setting. Biased agonist. A ligand that binds to a receptor and signals to a variable extent through both G protein-dependent and G protein-independent pathways. A ligand may be ''weakly biased,'' i.e., signaling is mainly via G proteins or ''perfectly biased,'' i.e., the ligand is an inverse agonist of the G protein-coupled pathway as well as an agonist of the G protein-independent pathways. Note. The categorization of ligands can be dependent on the type of assay used, the cell type in which the receptor has been expressed, expression levels, and the sensitivity and dynamic range of the assay used to detect downstream signaling events.
order of potency to the wild-type receptor and can couple efficiently to G proteins . It is not feasible to perform crystallography on human b 1 AR due to its extreme instability (Serrano-Vega and Tate, 2009), but the high sequence identity between the receptors (82%) in the transmembrane domains and loop regions (except most of cytoplasmic loop 3) shows b 1 AR-m23 is an excellent model for studying ligand- receptor interactions. Indeed, crystal structures of b 1 AR-m23 (Warne et al., 2008) and b 2 AR-T4L (Cherezov et al., 2007) show high similarity in the transmembrane domains (rmsd 0.7 Å ) and especially in the region of the ligand binding pocket (rmsd of 0.25 Å for 78 Ca atoms). None of the mutations in b 1 AR-m23 are in the ligand binding pocket and none of the sites of the mutations show a conformational change when comparing the structures of b 1 AR-m23 and b 2 AR-T4L.
Receptors were expressed, purified and crystallized as previously described. The cocrystal structures of b 1 AR44-m23 bound to either bucindolol or carvedilol were solved at resolutions of 3.2 and 2.3 Å , respectively ( Figure 2 and Table 1 
Structure
Biased Agonist-Bound b1-Adrenoceptor Structures complexed with either antagonists or with a covalently bound agonist. Thus, the structures presented here of b 1 AR bound to either bucindolol or carvedilol show in detail the ligand-receptor interactions (see below), but they do not define a new conformation of the receptor involved in G protein-independent signaling. It is likely that a complex of a phosphorylated bAR with arrestin will be required to fully understand the conformational change induced by the binding of biased agonists, because the signaling conformation of the receptor that allows arrestin binding is likely to be transient. This is consistent with the observation that the binding of a G protein or analog was required to obtain the structure of an R* state of b 2 AR (Rasmussen et al., 2011a (Rasmussen et al., , 2011b , while the structure of b 2 AR bound to a covalent agonist is in the R state (Rosenbaum et al., 2011) . Therefore, it seems unlikely that any key conformational changes are missing due to the presence of the thermostabilizing mutations. In contrast to the bARs, some receptors evince considerable conformational changes when crystallized in the presence of an agonist.
For example, the structure of the adenosine A 2A receptor bound to an agonist is clearly in an R*-like state, without the requirement for binding a G protein or G protein mimetic (Lebon et al., 2011; Xu et al., 2011) .
Ligand Binding in the Catecholamine Binding Pocket
The structures of bAR ligands are often very similar, particularly in the region of the secondary amine and b-hydroxyl groups and these are also conserved in bucindolol and carvedilol (Figure 1 ). The cocrystal structures show that their secondary amine and b-hydroxyl groups form potential hydrogen bonds with Asp121 3.32 and Asn329 7.39 and their ''head groups'' (equivalent to the catechol moiety in adrenaline) occupy a position adjacent to H5 (Figure 3) . Thus, both ligands exhibit the same general mode of binding observed for other bAR antagonists (Davis et al., 2007) . depicted in the carvedilol-bound structure in which the amide oxygen faces toward H5. In this configuration a potential steric clash with the ligand is avoided, this conformation could be dependent on the nature of the ligand.
Structure
Biased Agonist-Bound b1-Adrenoceptor Structures cocrystallized with either b 1 AR or b 2 AR (Cherezov et al., 2007; Hanson et al., 2008; Moukhametzianov et al., 2011; Wacker et al., 2010; Warne et al., 2008) . Previously, we showed that binding of a full agonist to b 1 AR resulted in three differences in receptor conformation compared to when an antagonist was bound, namely the rotamer conformation changes of Ser212 forms a hydrogen bond directly to the ligand (Figure 4) . However, the configuration of Ser212 5.43 is similar to that seen in the agonist-bound structures where it makes a potential hydrogen bond to Asn310 6.55 . A recently determined structure of b 1 AR with cyanopindolol bound in lipidic meso phase at a resolution of 2.1 Å (J.L. Miller and C.G.T., unpublished data) also shows this alternative rotamer conformation of Ser212 5.43 compared to the previous structure of cyanopindolol-bound b 1 AR determined in detergent (Warne et al., 2008) ; these data suggest that Ser212 5.43 can also be in this alternative conformation with an antagonist bound, and the configuration of Ser212 5.43 is therefore unlikely to represent an agonist-specific conformation. Both the bucindolol and carvedilol bound structures also do not exhibit the contraction of the binding pocket observed in the structures with full and partial agonists bound. It is therefore clear that the ligands do not induce the initial conformational changes in the receptor that are characteristic of agonists that activate G proteins. Bucindolol has been variously reported as being either an inverse agonist or partial agonist of the b 1 AR, depending on the system or tissue studied (Andreka et al., 2002; Engelhardt et al., 2001; Galandrin et al., 2008; Maack et al., 2000 Maack et al., , 2003 . However, in both bucindolol-bound and carvedilol-bound b 1 AR structures, the characteristic rotamer conformation change of Ser215 5.46 observed in structures with a full agonist bound is sterically blocked by the ligand, which is a characteristic of bAR inverse agonists .
Ligand Binding in the Extended Ligand Binding Pocket
Both bucindolol and carvedilol, unlike all other antagonists cocrystallized with bARs, have bulky aromatic substituents at their amine ends that make additional contacts in the extended ligand binding pocket composed of residues in helices 2, 3, and 7 and extracellular loop 2 (Figure 4 ). The additional contacts are detailed along with all other ligand-receptor contacts in Table 2 . It therefore seems logical to propose that the ability of bucindolol and carvedilol to stimulate G protein-independent signaling resides in the extensions in the tail region of the ligand that are absent from all other antagonists. However, it is difficult to say how these additional contacts might promote G proteinindependent signaling, because the conformations that might finally promote the binding of arrestin or other signaling proteins are currently unknown. However, it seems plausible that the additional contacts may result in an increased probability of subtle conformational changes that might be transmitted to the receptor's C terminus, where phosphorylation by GPCR-specific kinases promotes binding of arrestin and signaling (Granier et al., 2007; Nobles et al., 2011) . Bias of conventional G protein agonists of bARs toward the arrestin-signaling pathway has been investigated and methods to discern levels of G protein-independent activity that are relatively low compared to the dominant G protein-signaling activity are being developed. This has led to the categorization of a number of ligands that can activate both G protein-coupled and G protein-independent pathways, but to different extents . However, currently there is not a comprehensive list of the propensity of all bAR ligands for inducing signaling via G protein-independent pathways. So far, bias toward arrestin signaling among conventional G protein agonists has only been detected in ligands with either ethyl substitutions at the Ca, or amine-end substituents, such as those present in bucindolol and carvedilol (Drake et al., 2008; Rajagopal et al., 2011) . Of the conventional G protein agonists that have been cocrystallized previously with either b 1 AR or b 2 AR, dobutamine, isoprenaline and salbutamol have been identified as nonbiased agonists of the b 2 AR . The structure of b 1 AR bound to carmoterol has been Table 2 .
Structure
Biased Agonist-Bound b1-Adrenoceptor Structures determined , but this ligand has not been tested for signaling bias. However, formoterol, which is weakly arrestin biased, is structurally identical to carmoterol apart from a minor difference in its head group; both ligands have the same methoxyphenyl amine end extension (see Figure 1 for the structures) (Rajagopal et al., 2010) . The cocrystal structure of carmoterol with the b 1 AR indicates additional interactions of the methoxyphenyl group with extracellular loop 2 (EL2) as well as H7, and NMR data suggest that formoterol's methoxyphenyl group also interacts with residues on EL2 of the b 2 AR (Bokoch et al., 2010) . Thus, of the three ligands with amineend extensions that bind in the extended ligand binding pocket for which there are cocrystal structures and that have been examined for bias, bucindolol and carvedilol are biased agonists, whereas dobutamine is not. As in all probability, formoterol, which also shows weak arrestin bias also binds to EL2, one structural feature that may correlate with agonist bias is that bucindolol, carvedilol, and most likely formoterol all interact with EL2, whereas dobutamine does not. Whether this observation extends to other biased agonists will require further detailed characterization of more bAR ligands with both b 1 AR and b 2 AR rather than just a limited few.
While this manuscript was in review, a related manuscript appeared (Liu et al., 2012) , which detailed 19 F-NMR studies on b 2 AR bound to various ligands. Specific Cys residues in detergent-solubilized, purified b 2 AR were covalently modified with trifluoroethanethiol and then 19 F spectra were collected in the presence of inverse agonists, agonists, or biased agonists. The most significant difference observed when an inverse agonist was bound compared to when a biased agonist was bound was a change in the spectrum of 19 F-labeled Cys327; this residue is in the short linker between H7 and H8. These data indicate that the environment around Cys327 is different when a biased agonist is bound compared to when an inverse agonist is bound, which is consistent with the interpretation of the structural data presented here and previous biochemical data (Granier et al., 2007; Nobles et al., 2011) .
Understanding the Effects of the Arg389Gly
Polymorphism in Human b 1 AR The high-resolution of the b 1 AR-carvedilol complex fortuitously also allows us to suggest a mechanism for the difference in pharmacology in the frequently occurring Arg389Gly polymorphism of the human b 1 AR. The more common b 1 AR-Arg389 variant has a slightly higher basal G protein activity and a 3-fold increase in agonist response compared to the b 1 AR-Gly389 variant (Mason et al., 1999) . It has been suggested that the affected residue is in an area important for G protein coupling (Mason et al., 1999) , but it is now clear from the structure of the b 2 AR-Gs complex that this is not the case (Rasmussen et al., 2011b) . Therefore, the differences in pharmacology between the Arg/Gly variants must lie within the receptor itself.
The human b 1 AR residue affected by the polymorphism, Arg389
8.56 , is equivalent to Arg355 8.56 in the turkey b 1 AR and it which is consistent with the formation of the hydrogen bond to Arg355 8.56 observed in the structure with bound carvedilol. Increased thermostability of b 1 AR is likely to reflect a decrease in the global flexibility of the whole receptor. Thus, changes in thermostability due to mutations at the H1-H8 interface suggests that analogous changes in homologous receptors may also change the global dynamics of these receptors. These observations in the avian b 1 AR probably apply to human b 1 AR and b 2 AR as the equivalent residues to Arg68 1.59 are Lys85 1.59 and Lys60 1.59 . Thus, the Arg/Gly389 polymorphism in human b 1 AR will similarly alter the packing between H1 and H8, which could result in changes in the dynamics of the receptor, with the barrier to formation of the R* state perhaps being lower in the b 1 ARArg389 variant. This is indeed what has been observed pharmacologically and biochemically in a number of studies (Liggett et al., 2006; Rochais et al., 2007; Swift et al., 2008) . It has also been observed that carvedilol is a more efficient inverse agonist of the human b 1 AR-Arg389 isoform than are metoprolol and bisoprolol (Rochais et al., 2007) , two beta blockers that do not have extensions at their amine ends (see Figure 1 ). These findings have led to interest in the potential of genetically targeted therapies for heart failure with bucindolol or carvedilol (DeGeorge and Koch, 2007; Pleger and Koch, 2006 
Conclusions
The structures of b 1 AR bound to either bucindolol or carvedilol show that both of these ligands make additional contacts to helices 2, 3, and 7 and extracellular loop 2 compared to other structurally characterized bAR inverse agonists. Overall the structures show no conformational change when compared to other b 1 AR antagonist structures, but it is probable that the additional interactions in the extended ligand binding pocket might increase the likelihood of subtle conformational changes that result in enhanced arrestin binding and G protein-independent signaling. The fact that both bucindolol and carvedilol bind to b 1 AR in a similar manner to other bAR G protein antagonists, yet they can stimulate signaling via G protein-independent pathways while apparently inhibiting G protein coupling, strongly supports the contention that arrestin can bind to a different conformation of the receptor to that bound by G proteins.
EXPERIMENTAL PROCEDURES Expression, Purification, and Crystallization
The turkey (Meleagris gallopavo) b 1 AR construct, b44-m23, contains six thermostabilizing point mutations, two point mutations which improve receptor expression and homogeneity, and truncations at the N terminus, inner loop 3 and C terminus . Baculovirus expression and purification were all performed as described previously, with the detergent exchanged to Hega-10 (0.35%) on the alprenolol Sepharose affinity column (Warne et al., 2003 (Warne et al., , 2008 (Warne et al., , 2009 . Purified receptor was competitively eluted from the alprenolol Sepharose column with either bucindolol or carvedilol, but this was difficult because of the poor solubility of the ligands. Ligands were added to saturation from 20 mg/ml DMSO stock solutions to the elution buffer (10 mM Tris-HCl [pH 7.4], 100 mM NaCl, 0.1 mM EDTA, 0.35% Hega-10) with rapid stirring. The approximate final concentrations of the ligands in the elution buffer were 10 mM for carvedilol and 50 mM for bucindolol. Receptor was concentrated to 20 mg/ml in 10 mM Tris-HCl (pH 7.6), 100 mM NaCl, 0.1 mM EDTA, 0.35% Hega-10. Before crystallization, Hega-10 was added to 0.5%. Crystals were grown at 4 C by vapor diffusion in sitting drops with 150 nl receptor + 150 nl precipitant (0.1 M bicine [pH 9.0], 25% PEG 600 in both cases) and cryoprotected by addition of 60% PEG 600 for 1 min before mounting on Hampton CrystalCap HT loops and cryocooling in liquid nitrogen.
Data Collection, Structure Solution, and Refinement For both complexes, diffraction data were collected from a single cryocooled crystal (100 K) at the European Synchrotron Radiation Facility, Grenoble, France, with a Mar 225 CCD detector on beamline ID23-2 (wavelength, 0.8726 Å ) using a 10 mm focused beam. The microfocus beam was required for the location of the best diffracting parts of crystals, as well as allowing wedges of data (20-80 ) to be collected from different positions on the crystal. 
Structure
Biased Agonist-Bound b1-Adrenoceptor Structures For the b 1 AR crystals grown in the presence of bucindolol or carvedilol, 9 or 16 wedges of data from single crystals were merged, respectively. Images were processed with MOSFLM (Leslie, 2006) and SCALA (Evans, 2006) . Both structures were solved by molecular replacement with PHASER using the b 1 AR44-m23 structure with the agonist carmoterol bound (PDB code 2Y02) as a starting model (McCoy et al., 2007) . Refinement, rebuilding and validation were carried out with REFMAC5 (Murshudov et al., 1997) , COOT (Emsley and Cowtan, 2004) and MOLPROBITY (Davis et al., 2007) . Noncrystallographic symmetry restraints were applied as appropriate between the two monomers in the asymmetric unit for both structures, using the electron density maps and R free values to judge which residues should be excluded. The two independent copies of the receptor in the asymmetric unit are very similar for the bucindolol complex, although the ligand density was better defined for monomer A. In the carvedilol complex, there is a distortion of the ligand binding pocket in monomer A due to lattice contacts and monomer B represents the more physiologically relevant conformation.
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Coordinates and structure factors have been submitted to the PDB database under accession codes 4AMI and 4AMJ for b44-m23 bound to either bucindolol or carvedilol, respectively.
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